Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM.

Front Pharmacol. 2010 Nov 2;1:129. doi: 10.3389/fphar.2010.00129. eCollection 2010.

2.

Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption.

Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, Berndt SI, Boerwinkle E, Chanock S, Chatterjee N, Couper D, Curhan G, Heiss G, Hu FB, Hunter DJ, Jacobs K, Jensen MK, Kraft P, Landi MT, Nettleton JA, Purdue MP, Rajaraman P, Rimm EB, Rose LM, Rothman N, Silverman D, Stolzenberg-Solomon R, Subar A, Yeager M, Chasman DI, van Dam RM, Caporaso NE.

PLoS Genet. 2011 Apr;7(4):e1002033. doi: 10.1371/journal.pgen.1002033. Epub 2011 Apr 7.

3.

Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption.

Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KK, Franke B, den Heijer M, Kovacs P, Stumvoll M, Mägi R, Yanek LR, Becker LC, Boyd HA, Stacey SN, Walters GB, Jonasdottir A, Thorleifsson G, Holm H, Gudjonsson SA, Rafnar T, Björnsdottir G, Becker DM, Melbye M, Kong A, Tönjes A, Thorgeirsson T, Thorsteinsdottir U, Kiemeney LA, Stefansson K.

Hum Mol Genet. 2011 May 15;20(10):2071-7. doi: 10.1093/hmg/ddr086. Epub 2011 Feb 28.

4.

Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.

Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, McGuire V, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM.

Eur J Neurol. 2011 May;18(5):756-65. doi: 10.1111/j.1468-1331.2011.03353.x. Epub 2011 Jan 31.

5.

CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.

Lin KM, Tsou HH, Tsai IJ, Hsiao MC, Hsiao CF, Liu CY, Shen WW, Tang HS, Fang CK, Wu CS, Lu SC, Kuo HW, Liu SC, Chan HW, Hsu YT, Tian JN, Liu YL.

Pharmacogenomics. 2010 Nov;11(11):1535-43. doi: 10.2217/pgs.10.128.

PMID:
21121774
6.

CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme.

Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG.

Pharmacogenet Genomics. 2010 Nov;20(11):647-64. doi: 10.1097/FPC.0b013e32833e90eb.

PMID:
20881513
7.

Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.

Djordjevic N, Ghotbi R, Jankovic S, Aklillu E.

Eur J Clin Pharmacol. 2010 Jul;66(7):697-703. doi: 10.1007/s00228-010-0823-4.

PMID:
20390257
8.

Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations.

Jorge-Nebert LF, Jiang Z, Chakraborty R, Watson J, Jin L, McGarvey ST, Deka R, Nebert DW.

Hum Mutat. 2010 Jan;31(1):27-40. doi: 10.1002/humu.21132.

9.

Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region.

Yoshinari K, Yoda N, Toriyabe T, Yamazoe Y.

Biochem Pharmacol. 2010 Jan 15;79(2):261-9. doi: 10.1016/j.bcp.2009.08.008. Epub 2009 Aug 12.

PMID:
19682433
10.

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

Laika B, Leucht S, Heres S, Schneider H, Steimer W.

Pharmacogenomics J. 2010 Feb;10(1):20-9. doi: 10.1038/tpj.2009.32. Epub 2009 Jul 28.

PMID:
19636338
11.

Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Res. 2009 Nov;124(5):588-91. doi: 10.1016/j.thromres.2009.06.012. Epub 2009 Jul 23.

PMID:
19631365
12.

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB.

J Clin Psychopharmacol. 2009 Aug;29(4):319-26. doi: 10.1097/JCP.0b013e3181acc372.

PMID:
19593168
13.

Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E.

AAPS J. 2009 Sep;11(3):481-94. doi: 10.1208/s12248-009-9127-y. Epub 2009 Jul 10. Review.

14.

Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers.

Ghotbi R, Gomez A, Milani L, Tybring G, Syvänen AC, Bertilsson L, Ingelman-Sundberg M, Aklillu E.

Pharmacogenomics J. 2009 Jun;9(3):208-17. doi: 10.1038/tpj.2009.4. Epub 2009 Mar 10.

PMID:
19274061
15.

Coffee, CYP1A2 genotype and risk of myocardial infarction.

El-Sohemy A, Cornelis MC, Kabagambe EK, Campos H.

Genes Nutr. 2007 Oct;2(1):155-6. doi: 10.1007/s12263-007-0043-4. No abstract available.

16.

Coffee, caffeine-related genes, and Parkinson's disease: a case-control study.

Facheris MF, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Rocca WA, Maraganore DM.

Mov Disord. 2008 Oct 30;23(14):2033-40. doi: 10.1002/mds.22247.

17.

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.

Zanger UM, Turpeinen M, Klein K, Schwab M.

Anal Bioanal Chem. 2008 Nov;392(6):1093-108. doi: 10.1007/s00216-008-2291-6. Epub 2008 Aug 10. Review.

PMID:
18695978
18.

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.

Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, Bailey WL, Tantry US, Gurbel PA.

J Am Coll Cardiol. 2008 Aug 12;52(7):531-3. doi: 10.1016/j.jacc.2008.04.045.

19.

Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements.

Yoshinari K, Ueda R, Kusano K, Yoshimura T, Nagata K, Yamazoe Y.

Biochem Pharmacol. 2008 Jul 1;76(1):139-45. doi: 10.1016/j.bcp.2008.04.005. Epub 2008 Apr 16.

PMID:
18502397
20.

Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.

Gunes A, Dahl ML.

Pharmacogenomics. 2008 May;9(5):625-37. doi: 10.2217/14622416.9.5.625. Review.

PMID:
18466106

Supplemental Content

Support Center